Related Experiment Video
Updated: Jun 7, 2025

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion
Published on: July 27, 2021
CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced
Lindsey M Pale1, Jude B Khatib1, Alexandra Nusawardhana1
1Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
Abstract:
Treatment with genotoxic agents, such as platinum compounds, is still the mainstay therapeutical approach for the majority of cancers. Our understanding of the mechanisms of action of these drugs is, however, imperfect and continuously evolving. Recent advances highlighted single-stranded DNA (ssDNA) gap accumulation as a potential determinant underlying cisplatin chemosensitivity, at least in some genetic backgrounds, such as BRCA mutations. Cisplatin-induced ssDNA gaps form upon restart of DNA synthesis downstream of cisplatin-induced lesions through repriming catalyzed by the PRIMPOL enzyme. Here, we show that PRIMPOL overexpression in otherwise wild-type cells results in accumulation of cisplatin-induced ssDNA gaps without sensitizing cells to cisplatin, suggesting that ssDNA gap accumulation does not confer cisplatin sensitivity in BRCA-proficient cells. To understand how ssDNA gaps may cause cellular sensitivity, we employed CRISPR-mediated genome-wide genetic screening to identify factors which enable the cytotoxicity of cisplatin-induced ssDNA gaps. We found that the helicase HELQ specifically suppresses cisplatin sensitivity in PRIMPOL-overexpressing cells, and this is associated with reduced ssDNA accumulation. We moreover identify RAD52 as a mediator of this pathway. RAD52 promotes ssDNA gap accumulation through a BRCA-mediated mechanism. Our work identified the HELQ-RAD52-BRCA axis as a regulator of ssDNA gap processing and cisplatin sensitization.
Insights
Cisplatin resistance in cancer may involve single-stranded DNA (ssDNA) gaps. The HELQ-RAD52-BRCA pathway regulates these gaps, offering new targets for overcoming cisplatin resistance in BRCA-proficient cells.
Area of Science:
- Molecular Biology
- Cancer Research
- DNA Repair
Background:
- Platinum compounds like cisplatin are crucial cancer treatments, but their precise mechanisms and resistance pathways are not fully understood.
- Accumulation of single-stranded DNA (ssDNA) gaps has emerged as a potential factor in cisplatin chemosensitivity, particularly in BRCA-mutated cancers.
- The enzyme PRIMPOL catalyzes repriming, leading to ssDNA gap formation downstream of cisplatin lesions during DNA synthesis restart.
Purpose of the Study:
- To investigate whether ssDNA gap accumulation directly confers cisplatin sensitivity in BRCA-proficient cells.
- To identify genetic factors that mediate the cytotoxicity of cisplatin-induced ssDNA gaps using genome-wide screening.
- To elucidate the regulatory axis controlling ssDNA gap processing and its impact on cisplatin sensitization.
Main Methods:
- CRISPR-mediated genome-wide genetic screening was employed to identify genes modulating cisplatin sensitivity.
- Overexpression of PRIMPOL in wild-type cells was used to study ssDNA gap accumulation.
- Western blotting and DNA combing techniques were utilized to assess ssDNA gap formation and processing.
Main Results:
- PRIMPOL overexpression in wild-type cells led to ssDNA gap accumulation but did not sensitize cells to cisplatin, indicating gap accumulation alone is insufficient for sensitivity in BRCA-proficient cells.
- The helicase HELQ was identified as a suppressor of cisplatin sensitivity in PRIMPOL-overexpressing cells, correlating with reduced ssDNA accumulation.
- RAD52 was identified as a mediator, promoting ssDNA gap accumulation via a BRCA-dependent mechanism.
Conclusions:
- The HELQ-RAD52-BRCA axis plays a critical role in regulating ssDNA gap processing and influencing cisplatin sensitization.
- Understanding this axis provides insights into mechanisms of cisplatin resistance and potential therapeutic strategies for BRCA-proficient cancers.
- Targeting the HELQ-RAD52-BRCA pathway could offer novel approaches to enhance the efficacy of platinum-based chemotherapy.
More Related Videos
Related Concept Videos
Homologous Recombination
Fixing Double-strand Breaks
DNA Damage can Stall the Cell Cycle
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Long-patch Base Excision Repair
Restarting Stalled Replication Forks

